Sigma Planning Corp’s Arbutus Biopharma ABUS Stock Holding History

Sigma Planning Corp’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,000	Closed	-$30K	–	1264
2022 Q2	$30K	Hold	11,000	–	–	﹤0.01%	1264
2022 Q1	$33K	Hold	11,000	–	–	﹤0.01%	1345
2021 Q4	$43K	Hold	11,000	–	–	﹤0.01%	1361
2021 Q3	$47K	Sell	11,000 -15,000	-58%	-$50K	﹤0.01%	1350
2021 Q2	$79K	Sell	26,000 -290	-1%	-$898	﹤0.01%	1373
2021 Q1	$88K	Buy	+26,290	New	+$101K	﹤0.01%	1288

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sigma Planning Corp's ABUS Position: Q3 2022 in Review

Sigma Planning Corp sold out of Arbutus Biopharma (ABUS) in Q3 2022, closing a stake of 11,000 shares — an estimated $30K sold.

Sigma Planning Corp first reported a position in ABUS in Q1 2021 and held it in 6 quarters. The position peaked at $88K in Q1 2021. 127 funds tracked by Wall St. Rank hold ABUS as of Q3 2022.

Sigma Planning Corp reported no remaining Arbutus Biopharma position as of Q3 2022 after selling out during the quarter.
Sigma Planning Corp sold 11,000 Arbutus Biopharma shares in Q3 2022, an estimated $30K.
Sigma Planning Corp first reported a position in Arbutus Biopharma in Q1 2021 and held it in 6 quarters.
Sigma Planning Corp's Arbutus Biopharma position peaked at $88K in Q1 2021.
127 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2022.

Based on Sigma Planning Corp's 13F filing for Q3 2022, filed 10 Nov 2022.